For example, metformin can increase the level of bone formation marker in T2DM patients (146), liraglutide has an anti-resorptive effect on bone turnover in patients with T2DM (147), GLP-1 receptor agonists can increase BMD at multiple sites of the body in T2DM patients (148), denosumab can significantly increase BMD and decrease vertebral fracture risk in postmenopausal women with osteoporosis and diabetes (62), etc. LLLT can improve implant stability in patients with diabetes in 6 months trial (149). This evidence concerns the gene GLP1R and diabetes mellitus.